4D Molecular Therapeutics(FDMT) Prnewswire·2025-02-04 20:55Group 1 - Pomerantz LLP is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1] - On January 13, 2024, BMO Capital Markets downgraded 4D to market perform from outperform due to concerns over the limited durability of its wet age-related macular degeneration candidate 4D-150 and increased competition in the market [2] - Following the downgrade, 4D's stock price fell by 4.76 per share on January 13, 2025 [2] Group 2 - The Pomerantz Firm is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for the rights of victims of securities fraud and corporate misconduct [3]